Insider Selling: Heartflow (NASDAQ:HTFL) CFO Sells $297,325.60 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 5,876 shares of Heartflow stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $50.60, for a total value of $297,325.60. Following the transaction, the chief financial officer owned 248,683 shares in the company, valued at approximately $12,583,359.80. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total value of $1,368,462.60.

Heartflow Trading Down 1.6%

Shares of NASDAQ HTFL traded down $0.80 during mid-day trading on Friday, reaching $48.91. 1,406,810 shares of the company’s stock were exchanged, compared to its average volume of 1,541,654. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $51.78. The firm has a market capitalization of $4.25 billion and a price-to-earnings ratio of -26.73. The business has a fifty day simple moving average of $33.50 and a 200 day simple moving average of $29.79.

Heartflow (NASDAQ:HTFL) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.Heartflow’s revenue for the quarter was up 47.7% on a year-over-year basis. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Canaccord Genuity Group lifted their price target on Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Morgan Stanley increased their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Finally, Robert W. Baird set a $45.00 target price on Heartflow in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.43.

Institutional Investors Weigh In On Heartflow

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Heartflow during the 4th quarter worth about $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Heartflow in the fourth quarter valued at about $45,000. Essential Partners LLC bought a new stake in Heartflow during the first quarter worth about $57,000. Legal & General Group Plc acquired a new position in Heartflow during the third quarter valued at approximately $59,000. Finally, Strs Ohio bought a new position in Heartflow in the fourth quarter valued at approximately $99,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.